Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-week dose-ranging study of oral QBW251 in COPD patients on triple inhaled therapy
2018-003197-28Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Icenticaftor in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Novartis. Primary endpoint: Change from baseline in trough FEV1 at Week 12. Started Jun 2019; status: completed.
02
Drugs
Icenticaftor
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2018-003197-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003197-28.